Long-term safety of Entyvio for treating ulcerative colitis or Crohn’s Disease
Gauree G Konijeti, MD, MPH
This is an observational study to assess the long-term safety of Entyvio (vedolizumab), or other similar biologic agents in patients with Ulcerative Colitis (UC) or Crohn’s Disease (CD). Physicians will prescribe vedolizumab or other biologic agents as part of the patients’ clinical care and will collect safety information for up to 7 years.
Be at least 18 years of age
Be starting treatment with vedolizmnab (Entyvio) or any biologic agent for UC or CD
Have received any prior treatment with vedolizumab (Entyvio)
Be enrolled in another clinical trial that involves treatment for UC or CD
Subjects will be asked to complete 2 questionnaires to evaluate their health status at every office visit and will continue to be routinely followed-up by their physician about every 6 months.